89 completed, 2 active not recruiting, 2 recruiting, 1 enrolling by invitation. 53 Phase 1, 40 Phase 2, 8 Phase 3, 1 Not applicable, 1 Phase 4.
Follow Influenza in Birds: new trials by email Literature Review of Influenza in Birds trials Research Report on Influenza in Birds
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Smart Analysis and Decision-Making for Emerging Infectious Diseases Multi-Agent Integrated Smart Toolkit for Emerging Infectious Diseases, Routine Practices - Emerging Infectious Diseases, COVID-19 | Not applicable | Enrolling by invitation | Peking University | 108 | 2026-08-10 | 2026-08-19 |
| A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults mRNA-1018-H5, Placebo - Influenza | Phase 3 | Active not recruiting | ModernaTX, Inc. | 4050 | 2026-03-23 | 2026-08-11 |
| Pandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial) H5N1 vaccine (Arepanrix, GSK), Placebo - Influenza (Pandemic), Avian Influenza | Phase 3 | Recruiting | University Health Network, Toronto | 120 | 2025-11-03 | 2025-12-18 |
| Immunogenicity and Safety of 2 Doses of Avian Influenza A (H5N1) Vaccine Administered 3 vs. 8 Weeks Apart H5N1 vaccine (Arepanrix), Saline (as a placebo) - H5N1 Influenza, H5N1 Virus | Phase 4 | Active not recruiting | Canadian Immunization Research Network | 312 | 2025-10-14 | 2026-01-16 |
| Safety and Immunogenicity of the Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented and Adjuvanted) in Adults and Older Adults Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented, and Adjuvanted) 7.5 mcg, Monovalent influenza vaccine type A (H5N8) 15 mcg, Placebo - Avian Influenza A Virus | Phase 1 / Phase 2 | Recruiting | Butantan Institute | 700 | 2025-09-10 | 2026-04-02 |
| A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healthy Adults H5 AC-Anhui RNA Vaccine, H5 Astrakhan RNA Vaccine, Sodium Chloride, 0.9% - Avian Influenza | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 80 | 2025-06-12 | 2026-06-12 |
| A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults Flu Pandemic mRNA_Dose level 1, Flu Pandemic mRNA_Dose level 2, Flu Pandemic mRNA_ Dose level 3. - Influenza, Human | Phase 1 / Phase 2 | Completed | GlaxoSmithKline | 991 | 2024-04-18 | 2026-02-05 |
| A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed aH5N6c on Day 1, aH5N6c on Day 22, Placebo on Day 22 - Influenza, Human, Influenza in Birds | Phase 2 | Completed | Seqirus | 260 | 2022-07-18 | 2026-05-13 |
| 2017 A/H7N9 IIV Revaccination A/H7N9, AS03, Phosphate Buffered Saline (PBS) diluent - Avian Influenza, Influenza Immunisation | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 304 | 2018-12-18 | 2021-07-30 |
| Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza A/H7N9, MF59, Phosphate Buffered Saline (PBS) diluent - Avian Influenza, Influenza Immunisation | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 372 | 2018-11-02 | 2021-05-17 |
| 2013/2017 H7N9 Prime-Boost Interval A/H7N9, AS03, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013 - Avian Influenza, Influenza Immunisation | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 180 | 2018-08-21 | 2021-08-02 |
| H5N1 With or Without Topical Aldara in Healthy Adults Aqueous Cream B.P., Imiquimod, Influenza Virus Vaccine, Monovalent A/H5N1 A/Vietnam/1203/04 - Avian Influenza, Influenza Immunisation | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 50 | 2018-06-13 | 2020-02-24 |
| Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59 VN, IN, dk/BANG - Influenza A Virus, H5N1 Subtype | Phase 2 | Completed | Biomedical Advanced Research and Development Authority | 720 | 2018-03-15 | 2020-07-14 |
| Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4 AS03, Inactivated influenza H7N9 vaccine, Influenza Virus Quadrivalent Inactivated Vaccine - Avian Influenza, Influenza | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 149 | 2018-02-20 | 2020-08-06 |
| Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly AS03, Inactivated influenza H7N9 vaccine, Phosphate Buffered Saline (PBS) diluent - Avian Influenza, Influenza Immunisation | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 720 | 2018-02-14 | 2024-09-19 |
| Panblok H7 Vaccine Adjuvanted With AS03 or MF59 3.75 ug Panblok H7, 7.5 ug Panblok H7, 15 ug Panblok H7 - Influenza, Human | Phase 2 | Completed | Biomedical Advanced Research and Development Authority | 366 | 2017-09-20 | 2020-05-06 |
| A Safety and Immunogenicity Study of IVACFLU-A/H5N1 IVACFLU-A/H5N1 vaccine, Placebo - Avian Influenza | Phase 2 / Phase 3 | Completed | Institute of Vaccines and Medical Biologicals, Vietnam | 930 | 2017-03-07 | 2019-05-21 |
| H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: Immunology AS03, MF59, Monovalent Influenza A/H5N8 vaccine - Avian Influenza | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 388 | 2017-01-09 | 2024-09-23 |
| Recombinant H7 Hemagglutinin Influenza Vaccine Trial Recombinant influenza hemagglutinin - Influenza, Avian | Phase 1 | Completed | Vaxine Pty Ltd | 150 | 2017-01-01 | 2019-05-07 |
| H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses AS03, Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203, Monovalent influenza A/H7N9 virus vaccine - Avian Influenza, H1N1 Influenza | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 30 | 2016-11-07 | 2024-10-09 |
Showing 20 of 96. Sign in to see all of them.
Influenza, Human (68) · Virus Diseases (14) · Orthomyxoviridae Infections (6) · Respiratory Tract Diseases (3) · RNA Virus Infections (2) · Respiratory Tract Infections (2) · COVID-19 (1) · Chikungunya Fever (1) · Communicable Diseases (1) · Communicable Diseases, Emerging (1) · Dengue (1) · Dyspnea (1) · Infections (1) · Mpox, Monkeypox (1)
Animal Diseases (96) · Bird Diseases (96) · Infections (95) · RNA Virus Infections (94) · Orthomyxoviridae Infections (90) · Virus Diseases (82) · Respiratory Tract Infections (66) · Respiratory Tract Diseases (65) · Pathological Conditions, Signs and Symptoms (3) · Disease Attributes (2) · Pathologic Processes (2) · Alphavirus Infections (1) · Arbovirus Infections (1) · Communicable Diseases (1) · Coronaviridae Infections (1)
Influenza Vaccines (8) · AS03 adjuvant (4) · MF59 oil emulsion (4) · Oseltamivir (3) · Sodium Chloride (3) · Vaccines (3) · Adjuvants, Pharmaceutic (2) · Aluminum Hydroxide (2) · arepanrix (2) · Blood Component Removal (1) · FluBlok (1) · Imiquimod (1) · Probenecid (1) · SE 1-step Futurabond M (1) · Saline Solution (1)
National Institute of Allergy and Infectious Diseases (NIAID) (45) · Novartis Vaccines (8) · Seqirus (4) · Alachua Government Services, Inc. (3) · Mahidol University (3) · St. Jude Children's Research Hospital (3) · Biomedical Advanced Research and Development Authority (2) · Green Cross Corporation (2) · Inovio Pharmaceuticals (2) · Vaxart (2) · Vical (2) · AVIR Green Hills Biotechnology AG (1) · Altimmune, Inc. (1) · Butantan Institute (1) · Canadian Immunization Research Network (1)
United States (60) · Thailand (7) · Australia (6) · China (3) · Finland (3) · Germany (3) · South Korea (3) · Canada (2) · Italy (2) · Japan (2) · Lebanon (2) · Russia (2) · Singapore (2) · United Kingdom (2) · Vietnam (2)
Ruth A. Karron, MD (4) · Don Guterwill, BS, MT (2) · Woo Joo Kim, MD, Ph.D (2) · Alexander Geisberger, MD (1) · Bob Taylor, MD (1) · Carlos Fierro, MD (1) · D. Nigel Thomas, Ph.D. (1) · David Liebowitz, MD, PhD (1) · Dimitar Sajkov, MD, PhD (1)
PMID 39756216, PMID 19540952, PMID 21975270, PMID 30968056, PMID 18237269, PMID 18260764, PMID 18400288, PMID 18576945, PMID 18808338, PMID 19210163, PMID 19416838, PMID 19464558, PMID 19569973, PMID 20810680, PMID 20819892, PMID 21282194, PMID 21386997, PMID 21606530, PMID 22542645, PMID 22777094, PMID 23357198, PMID 23369412, PMID 23536690, PMID 23633404, PMID 23633407, PMID 23723457, PMID 24041789, PMID 24047817, PMID 24224560, PMID 24533064, PMID 25662592, PMID 25734159, PMID 26432909, PMID 28099485, PMID 28533093, PMID 30955980, PMID 31155415, PMID 31194712, PMID 31255574, PMID 31812464, PMID 33852718, PMID 34174187, PMID 34711436, PMID 35115707, PMID 35455245, PMID 35465983, PMID 37466221, PMID 38181048, PMID 38537255, PMID 39798434
N01AI70005 (1), U19AI090023 (1)